BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| PARSONS CAPITAL MANAGEMENT INC/RI | 1,785 | $619,000 | 0.06% |
| FIRST TRUST ADVISORS LP | 129,793 | $44,991,000 | 0.06% |
| Cubist Systematic Strategies, LLC | 26,230 | $9,092,000 | 0.06% |
| Proficio Capital Partners LLC | 867 | $301,000 | 0.06% |
| WENDELL DAVID ASSOCIATES INC | 1,250 | $433,000 | 0.06% |
| SRS Capital Advisors, Inc. | 1,012 | $351,000 | 0.05% |
| XPONANCE, INC. | 7,435 | $2,577,000 | 0.05% |
| NISA INVESTMENT ADVISORS, LLC | 17,220 | $5,969,000 | 0.05% |
| BLAIR WILLIAM & CO/IL | 32,981 | $11,433,000 | 0.05% |
| Invesco Ltd. | 489,994 | $169,852,000 | 0.05% |
| Procyon Advisors, LLC | 666 | $231,000 | 0.05% |
| VAN ECK ASSOCIATES CORP | 53,032 | $18,383,000 | 0.05% |
| Tower Research Capital LLC (TRC) | 6,277 | $2,176,000 | 0.05% |
| GUGGENHEIM CAPITAL LLC | 17,673 | $6,126,000 | 0.05% |
| BlackRock Inc. | 4,287,606 | $1,486,255,000 | 0.05% |
| Man Group plc | 32,606 | $11,303,000 | 0.05% |
| AMALGAMATED BANK | 14,872 | $5,155,000 | 0.05% |
| FRANKLIN RESOURCES INC | 274,825 | $95,266,000 | 0.05% |
| LOOMIS SAYLES & CO L P | 73,295 | $25,407,000 | 0.05% |
| First Trust Direct Indexing L.P. | 953 | $330,000 | 0.05% |
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists BIO-TECHNE CORP's shareholders in Q2 2022. To view BIO-TECHNE CORP's shareholder history, click here.